Alnylam Shares Sink About 30% After a Surprise Guidance Cut

Shares of RNA-drug maker Alnylam Pharmaceuticals tumbled about 30% after the company unexpectedly trimmed its sales outlook, erasing roughly $12 billion in market value in a single day.

The stock fell to around $200 from a prior close of $286 on July 30. The trigger: Alnylam cut combined guidance for Amvuttra and Onpattro to $4.2–$4.5 billion from $4.4–$4.7 billion — a $200 million reduction. Second-quarter Amvuttra sales of $1.01 billion also came in about 3% below the roughly $1.05 billion analysts expected.

Why a small cut moved so much value

The disproportion is the story. A $200 million reduction on roughly $4.5 billion is about 4.4%, and the market removed 30% of the company’s value.

The explanation is how growth companies are valued. A stock priced on rapid future expansion carries a valuation reflecting years of assumed compounding, and the assumption matters far more than any single year’s revenue.

A guidance cut does not merely subtract $200 million from one year. It revises the growth rate applied to every subsequent year, and a small change in that rate compounds into a large change in present value.

The surprise element compounded it. An expected slowdown is already priced in; an unexpected one forces a rapid reassessment and tends to overshoot.

What TTR amyloidosis is

Alnylam competes in the market for transthyretin (TTR) amyloidosis, a condition that can damage the heart and nerves.

The disease occurs when transthyretin, a protein produced mainly by the liver, misfolds and deposits as amyloid fibrils in tissue. Where it deposits determines the presentation: nerves produce a progressive neuropathy, heart muscle produces a stiffening cardiomyopathy leading to heart failure.

Some cases are inherited through mutations destabilising the protein; others occur with age in people carrying normal transthyretin, and that form is substantially underdiagnosed — frequently mistaken for ordinary heart failure until imaging or biopsy identifies amyloid.

The competing mechanisms

Rivals include Pfizer’s Vyndamax and BridgeBio’s Attruby, and the approaches differ fundamentally.

Alnylam’s drugs use RNA interference to reduce production of transthyretin in the liver — less protein made, less available to misfold and deposit.

The competitors are stabilisers: small molecules binding transthyretin and holding it in its correctly folded shape so it does not come apart in the first place.

Both are logical. The practical differences are administration — an injectable given periodically versus a daily oral pill — and cost, with the oral small molecules generally cheaper to make.

What normalized demand means

Management indicated that an initial sales spike driven by pent-up demand had normalized.

The pattern is characteristic of a new treatment in a chronic disease. At launch, every diagnosed patient who has been waiting becomes eligible at once, producing a surge as the accumulated backlog is treated.

Once that prevalent pool is served, growth depends only on newly diagnosed patients — a much smaller flow. The transition from backlog to incidence is inevitable and its timing is difficult to forecast, which is why launches in this shape repeatedly surprise both companies and analysts.

Analysts caught off guard

“We knew expectations for 2026 were ambitious, but we weren’t expecting a guidance cut,” a Cantor Fitzgerald analyst wrote. A Jefferies analyst said the guidance raised real questions about the TTR outlook, adding that “the bull/bear debate…is real.”

Those responses are informative about the prior consensus: expectations were recognised as demanding, and nobody anticipated the company itself would be the one to lower them.

The underlying question

What the market must now judge is whether this is a maturing launch or the beginning of competitive share loss — and the two look similar in a single quarter.

Why TTR became such a contested market

The competitive intensity here reflects an unusual convergence: a disease that turned out to be far more common than believed, and three viable therapeutic mechanisms arriving within a few years.

Transthyretin amyloid cardiomyopathy was long regarded as rare. Wider use of a nuclear imaging technique that identifies cardiac amyloid without biopsy changed that, revealing meaningful numbers of older heart-failure patients whose disease had been attributed to other causes.

That reclassification created a large addressable population effectively overnight, and it is still expanding as awareness spreads and imaging is applied more routinely.

Three mechanisms now compete for it: silencers reducing production, stabilisers holding the protein folded, and depleters designed to clear amyloid already deposited. They are not strictly mutually exclusive, and whether they are eventually combined or compete head to head is unresolved.

Which is the real uncertainty behind the guidance cut. In a market growing this fast, distinguishing a company losing share from one whose launch phase has simply ended requires several more quarters of data than anyone currently has.

For a company long prized as a growth story in RNA interference, the reset is a reminder that even successful launches eventually settle into a slower, more competitive phase. Business news, not investment advice.